Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy
Open accessAbstract
“Neo RAS WT” refers to the loss of RAS mutations (MTs) following first-line treatment in metastatic colorectal cancer (mCRC). We evaluate the incidence and clinicopathological characteristics of Neo RAS WT mCRC using next-generation sequencing of plasma circulating tumor DNA. Patients with mCRC enrolled in the GOZILA study initially diagnosed with tissue RAS MT mCRC and received subsequent systemic therapy are eligible. Neo RAS WT is defined as the absence of detectable RAS MT in plasma and assessed in all eligible patients (Group A) and in a subgroup with at least one somatic alteration detected in plasma (Group B). Overall, 478 patients are included. Neo RAS WT prevalence is 19.0% (91/478) in Group A and 9.8% (42/429) in Group B. Absence of liver or lymph node metastasis and tissue RAS MTs other than KRAS exon 2 MTs are significantly associated with Neo RAS WT emergence. Overall, 1/6 and 2/6 patients with Neo RAS WT treated with anti-EGFR monoclonal antibodies (mAbs) show partial response and stable disease for ≥6 months, respectively. Neo RAS WT mCRC is observed at a meaningful prevalence, and anti-EGFR mAb-based therapy may be effective.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Factors associated with changes in RAS mutation status (mutant to wild-type) included the absence of liver or lymph node metastases and the presence of low-frequency RAS mutations (mutations other than KRAS exon 2).
“The factors associated with changes in RAS mutation status (mutant to wild-type) included the absence of liver or lymph node metastases and the presence of low-frequency RAS mutations (mutations other than KRAS exon 2) [61]”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2012) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,876 · see citing works
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · see citing works
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656 · see citing works
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885 · see citing works
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467 · see citing works
Self-citationPanitumumab–FOLFOX4 Treatment and <i>RAS</i> Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · see citing works
AACR Project GENIE: Powering Precision Medicine through an International Consortium
The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, André, F., Arnedos, M., Baras, A. S., Baselga, J., Bedard, P. L., Berger, M. F., Bierkens, M., Calvo, F., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0151 · Cited by 1,964 · see citing works
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,941 · see citing works
Hashiguchi, Y., Muro, K., Saitō, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,936 · see citing works
Self-citationEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · see citing works
Cervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · see citing works
Self-citationKRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · see citing works
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,079 · see citing works
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789 · see citing works
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682 · see citing works
Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Kato, K., Morizane, C., Esaki, T., Komatsu, Y., Kawamoto, Y., Takahashi, N., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1063-5 · Cited by 373 · see citing works
Self-citationNakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · see citing works
Self-citationPtashkin, R. N., Mandelker, D. L., Coombs, C. C., Bolton, K. L., Yelskaya, Z., Hyman, D. M., Solit, D. B., Baselga, J. M., Arcila, M. E., Ladanyi, M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2297 · Cited by 213 · see citing works
Laurent‐Puig, P., Pekin, D., Normand, C., Kotsopoulos, S. K., Nizard, P., Perez‐Toralla, K., Rowell, R. K., Olson, J., Srinivasan, P., Corre, D. L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0983 · Cited by 156 · see citing works
Clinical utility of circulating tumor DNA for colorectal cancer
Osumi, H., Shinozaki, E., Yamaguchi, K., & Zembutsu, H. (2019) · Cancer Science · doi:10.1111/cas.13972 · Cited by 150 · see citing works
Self-citationKim, M. J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J., Bang, S., Park, K. U., Kim, D., Kang, S., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 141 · see citing works
Biomarker concordance between primary colorectal cancer and its metastases
Bhullar, D., Barriuso, J., Mullamitha, S., Saunders, M. P., O’Dwyer, S., & Aziz, O. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.050 · Cited by 115 · see citing works
Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer
Bando, H., Nakamura, Y., Taniguchi, H., Shiozawa, M., Yasui, H., Esaki, T., Kagawa, Y., Denda, T., Satoh, T., Yamazaki, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00535 · Cited by 111 · see citing works
Self-citationBando, H., Kagawa, Y., Kato, T., Akagi, K., Denda, T., Nishina, T., Komatsu, Y., Oki, E., Kudo, T., Kumamoto, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0457-y · Cited by 92 · see citing works
Self-citationRaimondi, C., Nicolazzo, C., Belardinilli, F., Loreni, F., Gradilone, A., Mahdavian, Y., Gelibter, A. J., Giannini, G., Cortesi, E., & Gazzaniga, P. (2019) · Cancers · doi:10.3390/cancers11010042 · Cited by 51 · see citing works
Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S. (2022) · The Oncologist · doi:10.1093/oncolo/oyac077 · Cited by 43 · see citing works
Moati, É., Blons, H., Taly, V., Garlan, F., Renault, S., Pietrasz, D., Didelot, A., Garrigou, S., Saint, A., Pernot, S., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32657 · Cited by 41 · see citing works
Neoantigens elicit T cell responses in breast cancer
Morisaki, T., Kubo, M., Umebayashi, M., Yew, P. Y., Yoshimura, S., Park, J.-H., Kiyotani, K., Kai, M., Yamada, M., Oda, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91358-1 · Cited by 41 · see citing works
Self-citationOsumi, H., Vecchione, L., Keilholz, U., Vollbrecht, C., Alig, A. H. S., von Einem, J. C., Stahler, A., Striefler, J. K., Kurreck, A., Kind, A. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.05.010 · Cited by 36 · see citing works
Self-citationTaniguchi, H., Okamoto, W., Muro, K., Akagi, K., Hara, H., Nishina, T., Kajiwara, T., Denda, T., Hironaka, S., Kudo, T., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.10.004 · Cited by 33 · see citing works
Self-citationNakamura, Y., Okamoto, W., Denda, T., Nishina, T., Komatsu, Y., Yuki, S., Yasui, H., Esaki, T., Sunakawa, Y., Ueno, M., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00383 · Cited by 30 · see citing works
Self-citationBouchahda, M., Saffroy, R., Karaboué, A., Hamelin, J., Innominato, P. F., Saliba, F., Lévi, F., Bosselut, N., & Lemoine, A. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00400 · Cited by 29 · see citing works
Loree, J. M., Dowers, A., Tu, D., Jonker, D. J., Edelstein, D. L., Quinn, H., Holtrup, F., Price, T. J., Zalcberg, J. R., Moore, M. J., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2710 · Cited by 29 · see citing works
Gazzaniga, P., Raimondi, C., Urbano, F., & Cortesi, E. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00277 · Cited by 28 · see citing works
Nicolazzo, C., Barault, L., Caponnetto, S., Renzi, G. D., Belardinilli, F., Bottillo, I., Bargiacchi, S., Macagno, M., Grammatico, P., Giannini, G., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.014 · Cited by 27 · see citing works
Sunakawa, Y., Satake, H., Usher, J. L., Jaimes, Y. S., Miyamoto, Y., Nakamura, M., Kataoka, M., Shiozawa, M., Takagane, A., Terazawa, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100512 · Cited by 22 · see citing works
Self-citationNeoRAS: Incidence of RAS reversion from RAS mutated to RAS wild type.
Henry, J. T., Willis, J. A., Parseghian, C. M., Raghav, K. P. S., Johnson, B., Dasari, A. N., Stone, D., Jeyakumar, N., Coker, O., Raymond, V. M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.180 · Cited by 21 · see citing works
Nicolazzo, C., Belardinilli, F., Vestri, A., Magri, V., De Renzi, G., De Meo, M., Caponnetto, S., Di Nicolantonio, F., Cortesi, E., Giannini, G., et al. (2022) · Cancers · doi:10.3390/cancers14030802 · Cited by 21 · see citing works
Osumi, H., Ishizuka, N., Takashima, A., Kumekawa, Y., Nakano, D., Shiozawa, M., Denda, T., Sawada, R., Ouchi, K., Wakatsuki, T., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-063071 · Cited by 19 · see citing works
Self-citationNicolazzo, C., Barault, L., Caponnetto, S., Macagno, M., Renzi, G. D., Gradilone, A., Belardinilli, F., Cortesi, E., Nicolantonio, F. D., & Gazzaniga, P. (2020) · Cancers · doi:10.3390/cancers12123633 · Cited by 17 · see citing works
Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101718 · Cited by 16 · see citing works
Self-citationMontés, A. F., Lago, N. M., Gómez, J. D. L. C., Rúa, M. C., Castiñeiras, A. C., Villarroel, P. G., & Méndez, J. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz155.088 · Cited by 15 · see citing works
Ichimiya, S., Fujimura, A., Masuda, M., Masuda, S., Yasumatsu, R., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Yew, P. Y., et al. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1973491 · Cited by 14 · see citing works
Self-citationUdagawa, S., Ooki, A., Shinozaki, E., Fukuda, K., Yamaguchi, K., & Osumi, H. (2023) · Cancers · doi:10.3390/cancers15051473 · Cited by 14 · see citing works
Self-citationAoki, Y., Nakamura, Y., Denda, T., Ohta, T., Esaki, T., Shiozawa, M., Yamaguchi, K., Yamazaki, K., Sunakawa, Y., Kato, T., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00688 · Cited by 11 · see citing works
Self-citationWu, H.-T., Kalashnikova, E. V., Mehta, S., Salari, R., Sethi, H., Zimmermann, B. G., Billings, P. R., & Aleshin, A. A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.1525 · Cited by 9 · see citing works
Chemotherapy-induced Reversion of MutantRASto Wild-typeRASin Metastatic Colorectal Cancer
Sato, S., Mikayama, Y., Shiozawa, M., Nukada, S., Iguchi, K., Okamoto, H., Kohmura, T., Kazama, K., Tanaka, K., Oshima, T., et al. (2022) · Anticancer Research · doi:10.21873/anticanres.15740 · Cited by 9 · see citing works
Self-citationCaughey, B. A., Umemoto, K., Green, M. F., Ikeda, M., Lowe, M. E., Ueno, M., Niedzwiecki, D., Taniguchi, H., Walden, D. J., Komatsu, Y., et al. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-114 · Cited by 4 · see citing works
Self-citationYoshinami, Y., Osumi, H., Takashima, A., Sawada, R., Ouchi, K., Wakatsuki, T., Ooki, A., Nakayama, I., Fukuoka, S., Ogura, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.206 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., et al. (2025) · Cancers · doi:10.3390/cancers17030428 · Cited by 82 · see citing works
Ziranu, P., Pretta, A., Saba, G., Spanu, D., Donisi, C., Ferrari, P. A., Cau, F., D’Agata, A. P., Piras, M., Mariani, S., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157619 · Cited by 19 · see citing works
Palieri, R., Luca, M. D., Balestra, F., Panzetta, G., Lotesoriere, C., Rizzi, F. R., Ricci, A. D., Mastrogiacomo, R., Curri, M. L., Laghi, L., et al. (2025) · Oncology Reviews · doi:10.3389/or.2025.1702932 · Cited by 14 · see citing works
Ciardiello, D., Bielo, L. B., Napolitano, S., Latiano, T., Stefano, A. D., Tamburini, E., Toma, I., Bordonaro, R., RUSSO, A. E., Pisconti, S., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104511 · Cited by 13 · see citing works
Pesola, G., Epistolio, S., Cefalì, M., Trevisi, E., Dosso, S. D., & Frattini, M. (2024) · Cancers · doi:10.3390/cancers16233923 · Cited by 4 · see citing works
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS
Massaro, G., Venturini, J., Rossini, D., Vannini, A., Brugia, M., Lavacchi, D., Conticello, C., Valle, I., Ravizza, D., Pillozzi, S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104746 · Cited by 2 · see citing works
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2 · see citing works
Siringo, M., Meo, M. D., Bottillo, I., Grammatico, P., Cortesi, E., Nicolazzo, C., & Gazzaniga, P. (2025) · Cancers · doi:10.3390/cancers17071070 · Cited by 1 · see citing works
Farinea, G., Antón-Pascual, B., Villa, J. L. C., & Martínez, M. C. R. (2025) · BMJ Case Reports · doi:10.1136/bcr-2024-264115 · Cited by 1 · see citing works
Suzuki, K., Ooki, A., Shinozaki, E., Toyokawa, E., Yoshikawa, K., Shiozawa, M., Maeda, S., Yamaguchi, K., & Osumi, H. (2026) · Cancer Control · doi:10.1177/10732748261458456 · Cited by 1 · see citing works
Self-citationOutcomes of Broader Genomic Profiling in Metastatic Colorectal Cancer: A Portuguese Cohort Study
Roque, R., Santos, R. A., Santos, L. G., Coelho, R., Fernandes, I., Cunha, G. V., Gonçalves, M. M. D. S. L. B., Fraga, T., de Paulo, J. V., & Bonito, N. (2025) · DNA · doi:10.3390/dna5010004 · Cited by 1 · see citing works
Sato, T., Nagashima, F., Okano, N., Nishioka, M., Hayashi, M., Saito, Y., Hisamatsu, T., & Hironaka, S. (2025) · International Cancer Conference Journal · doi:10.1007/s13691-025-00826-2
Huang, A. H., Lee, G. Y., Lu, C. A., Şahin, İ. H., King, G. T., Safyan, R. A., Cohen, S. A., Zhen, D. B., Shankaran, V., Harris, W. P., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00646
Effect of sex differences on the emergence of ctDNA RAS mutations in RAS wild-type colorectal cancer
Iguchi, K., UCHIYAMA, M., Asari, M., Numata, K., & Shiozawa, M. (2026) · Scientific Reports · doi:10.1038/s41598-026-42920-2
Self-citationCancer biology and the principles of targeted cancer drug discovery
Davies, A., Jones, G., Krishnan, S., Krishnamoorthy, M., Maruggi, M., Kaneda, M., & Marjon, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00035-2
Ito, K., Kataoka, K., Muroi, Y., Koba, M., Fukumoto, Y., Imada, A., Song, J., Rao, Z., Osumi, H., Uchino, M., et al. (2026) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2026-003
Self-citationOsumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117112
Self-citation
- Authors
- Osumi, H., Shinozaki, E., Nakamura, Y., Esaki, T., Yasui, H., Taniguchi, H., Satake, H., Sunakawa, Y., Komatsu, Y., Kagawa, Y., Denda, T., Shiozawa, M., Satoh, T., Nishina, T., Goto, M., Takahashi, N., Kato, T., Bando, H., Yamaguchi, K., & Yoshino, T.
- Affiliations
- The Cancer Institute Hospital (JP)
- National Cancer Center Hospital East (JP)
- National Hospital Organization Kyushu Cancer Center (JP)
- Kobe Medical Center (JP)
- Aichi Cancer Center (JP)
- Kōchi University (JP)
- St. Marianna University School of Medicine (JP)
- Hokkaido University Hospital (JP)
- Osaka Prefectural Medical Center (JP)
- Chiba Cancer Center (JP)
- Kanagawa Cancer Center (JP)
- Osaka University Hospital (JP)
- Shikoku Cancer Center (JP)
- Osaka Medical and Pharmaceutical University Hospital (JP)
- Saitama Cancer Center (JP)
- Osaka National Hospital (JP)
- Corresponding author
- Shinozaki, Eiji
- Yoshino, Takayuki
- ORCID
- Venue
- Nature Communications
- Published
- 2024-07-13
- Volume
- 15
- Issue
- 1
- Pages
- 5885-5885
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC11246505
- OpenAlex
- W4400608706
- Cited by
- 17
- References
- 51
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 1
- FWCI
- 2.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Kanazawa University
- University of Tsukuba
- Saitama Medical University
- Japan Society for the Promotion of Science (22K08023)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, circulating tumor DNA, liquid biopsy, KRAS exon 2 mutation, anti-EGFR monoclonal antibody, first-line systemic therapy, liver metastasis, lymph node metastasis, treatment response, clinical predictors
- MeSH terms
- Circulating Tumor DNA, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Female, Humans, Japan, Liver Neoplasms, Lymphatic Metastasis, Male, Middle Aged, Mutation, Neoplasm Metastasis, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), High-Throughput Nucleotide Sequencing, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
